サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：脊髄刺激の世界市場-2023年～2030年
市場調査レポート
商品コード
1348006

脊髄刺激の世界市場-2023年～2030年

Global Spinal Cord Stimulation Market - 2023-2030

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
脊髄刺激の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

脊髄刺激（SCS）は比較的新しい技術で、原因が完全に治療できない場合や損傷を修復できない場合の慢性疼痛管理に役立ちます。脊髄刺激は、痛みの緩和と日常機能の改善をもたらします。

脊髄刺激療法は、脊髄の特定の神経線維を刺激するために軽い電流を使用します。脊髄刺激は、標的を絞った鎮痛に役立ちます。体幹や四肢の慢性難治性疼痛（片側または両側の疼痛を含む）の管理補助として適応されます。脊髄刺激は、全般的な生活の質や睡眠を改善し、鎮痛薬の必要性を減らすことができます。

ダイナミクス

先進機器の発売数の増加が市場成長を加速させる見込み

先進的な脊髄刺激装置は、慢性的な痛みに苦しむ患者に効率的な治療を提供するのに役立つため、装置に対する需要が増加し、市場成長が促進されます。例えば、医療技術の世界的リーダーであるMedtronic Plcは、2022年1月24日、糖尿病性末梢神経障害（DPN）に伴う慢性疼痛を治療するための2つの高度先進脊髄刺激装置、Intellis充電式神経刺激装置とVanta充電不要神経刺激装置を発表しました。

さらに、2022年10月12日、慢性疼痛治療のための包括的で人生を変えるソリューションを提供する世界の医療機器企業であるネブロ社は、脊髄刺激（SCS）システムSenza HFX iQを開発しました。センザHFX iQは、患者から学習する最初で唯一の人工知能ベースのSCSシステムです。

脊髄損傷の増加や、薬物療法に代わるものとして慢性疾患患者が脊髄刺激装置を採用するケースが増加していることも、市場成長を促進する要因として期待されています。

高額な治療費が市場成長の妨げになると予想される

治療費が高額になると、患者が脊髄刺激から他の低コストの薬剤や鎮痛剤に移行することで、市場成長に影響を与える可能性があります。ワシントン州労働産業局が資金提供した調査によると、脊髄刺激システムの移植にかかる総医療費は、患者1人当たり平均19,246～47,190米ドルです。

脊髄刺激に伴う合併症や髄液漏れなど、その他の要因が市場成長の妨げになることもあります。そのため、市場成長に影響を与えます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 先端機器の発売数の増加
    • 抑制要因
      • 治療手技の高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 デバイスの種類別

  • 充電式植込み型パルス発生器
  • 非充電式
  • 従来式植込み型パルス発生器
  • 高周波刺激装置

第8章 適応症別

  • 腰痛症（FBS）
  • 変性椎間板疾患
  • 複合性局所疼痛症候群（CRPS）
  • 術後疼痛
  • クモ膜炎
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 整形外科センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic Plc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Abbott Laboratories
  • Synapse Biomedical（SBI）
  • Boston Scientific Corporation
  • Curonix LLC,
  • Cirtec Medical
  • Nevro Corporation
  • Gimer Medical.
  • Beijing Pinchi Medical Equipment Co., Ltd.
  • Saluda Medical Pty Ltd.

第13章 付録

目次
Product Code: MD2176

Overview

Spinal cord stimulation (SCS) is a relatively new technology that can help manage chronic pain when the cause cannot be treated completely or the injury cannot be repaired. Spinal cord stimulation therapy offers relief and improved daily functioning.

Spinal cord stimulation uses a mild electrical current to stimulate certain nerve fibers in the spinal cord. Spinal cord stimulation helps in targeted pain relief. It is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. Spinal cord stimulation can improve overall quality of life and sleep and reduce the need for pain medicines.

Dynamics

Increased number of launches of advanced devices is expected to accelerate the market growth

Advanced spinal cord stimulators help provide efficient treatment to patients suffering from chronic pain, thus, increasing the demand for the devices and driving the market growth. For instance, on January 24, 2022, Medtronic Plc, a global leader in healthcare technology, introduced two highly advanced spinal cord stimulating devices, Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for treating chronic pain associated with diabetic peripheral neuropathy (DPN).

Furthermore, on October 12, 2022, Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the treatment of chronic pain, developed the Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients.

The increase in the number of spinal cord injuries and the increase in the adoption of spinal cord stimulators by chronic disease patients as an alternative to medication are the additional factors that are expected to drive the market growth.

High cost of the treatment procedure is expected to hinder market growth

The high cost of the treatment can affect the market growth by allowing the patients to shift from spinal cord stimulation to other low-cost drugs and painkillers. According to a study funded by the Washington State Department of Labor and Industries, the average total medical costs of implanting a spinal cord stimulating system range from $19,246-$47,190 per patient.

Other factors, such as complications associated with spinal cord stimulation and leakage in the spinal fluid, can hamper the market growth. Thus, it affects the market growth.

Segment Analysis

The global spinal cord stimulation market is segmented based on device type, indication, end-user, and region.

Rechargeable implantable pulse generator segment holds a significant position in the market share

The increase in the number of approvals of rechargeable implantable pulse generators is expected to hold a significant position in the market growth. For instance, BIOTRONIK, on April 19, 2023, received U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.

Additionally, on December 19, 2022, Abbott received the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Thus, an increase in the number of product approvals is expected to hold the segment in the dominant position.

Geographical Penetration

North America holds the largest market share in the global spinal cord stimulation market

North America holds a dominant market share due to the increase in the number of FDA approvals. Launches and distribution of a large number of products help make the treatment available to a number of individuals.

For instance, on January 19, 2022, Nevro Corp., a global medical device company, received FDA approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System for treating Non-Surgical Refractory Back Pain (NSRBP).

Additionally, on May 16, 2023, Abbott received the U.S. Food and Drug Administration (FDA) approval for expanding its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. Thus, increasing the number of FDA approvals is expected to drive the region's market share.

Competitive Landscape

Medtronic Plc, Abbott Laboratories, Synapse Biomedical (SBI), Boston Scientific Corporation, Curonix LLC, Cirtec Medical, Nevro Corporation, Gimer Medical., Beijing Pinchi Medical Equipment Co., Ltd., and Saluda Medical Pty Ltd. are the leading companies with significant market share.

Key Developments

  • On August 25, 2023, Medtronic plc, a global leader in healthcare technology, received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS).

COVID-19 Impact Analysis

COVID-19 has impacted the spinal cord stimulation market moderately. The treatment procedures have been postponed, and the follow-ups after the treatment procedures have been delayed. The development and manufacturing of the devices has been halted. This created a negative impact on the growth of the market.

Market Segmentation

By Device Type

  • Rechargeable implantable pulse generator
  • Conventional implantable pulse generator
  • Non-rechargeable
  • Radiofrequency stimulator

By Indication

  • Failed Back Syndrome (FBS)
  • Degenerative Disk Disease
  • Complex regional pain syndrome (CRPS)
  • Post-surgical pain
  • Arachnoiditis
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Orthopedic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global spinal cord stimulation market segmentation based on device type, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of spinal cord stimulation market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global spinal cord stimulation market report would provide approximately 61 tables, 59 figures, and 183 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of launches of advanced devices
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of the treatment procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Rechargeable implantable pulse generator *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-rechargeable
  • 7.4. Conventional implantable pulse generator
  • 7.5. Radiofrequency stimulator

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Failed Back Syndrome (FBS) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Degenerative Disk Disease
  • 8.4. Complex regional pain syndrome (CRPS)
  • 8.5. Post-surgical pain
  • 8.6. Arachnoiditis
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Orthopedic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abbott Laboratories
  • 12.3. Synapse Biomedical (SBI)
  • 12.4. Boston Scientific Corporation
  • 12.5. Curonix LLC,
  • 12.6. Cirtec Medical
  • 12.7. Nevro Corporation
  • 12.8. Gimer Medical.
  • 12.9. Beijing Pinchi Medical Equipment Co., Ltd.
  • 12.10. Saluda Medical Pty Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us